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Abstract
Background
The complications of Nonalcoholic Fatty Liver Disease (NAFLD) are dependent on the pres-
ence of advanced fibrosis. Given the high prevalence of NAFLD in the US, the optimal eval-
uation of NAFLD likely involves triage by a primary care physician (PCP) with advanced
disease managed by gastroenterologists.
Methods
We compared the cost-effectiveness of fibrosis risk-assessment strategies in a cohort of
10,000 simulated American patients with NAFLD performed in either PCP or referral clinics
using a decision analytical microsimulation state-transition model. The strategies included
use of vibration-controlled transient elastography (VCTE), the NAFLD fibrosis score (NFS),
combination testing with NFS and VCTE, and liver biopsy (usual care by a specialist only).
NFS and VCTE performance was obtained from a prospective cohort of 164 patients with
NAFLD. Outcomes included cost per quality adjusted life year (QALY) and correct classifi-
cation of fibrosis.
Results
Risk-stratification by the PCP using the NFS alone costs $5,985 per QALY while usual care
costs $7,229/QALY. In the microsimulation, at a willingness-to-pay threshold of $100,000,
the NFS alone in PCP clinic was the most cost-effective strategy in 94.2% of samples, fol-
lowed by combination NFS/VCTE in the PCP clinic (5.6%) and usual care in 0.2%. The NFS
based strategies yield the best biopsy-correct classification ratios (3.5) while the NFS/
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VCTE and usual care strategies yield more correct-classifications of advanced fibrosis at
the cost of 3 and 37 additional biopsies per classification.
Conclusion
Risk-stratification of patients with NAFLD primary care clinic is a cost-effective strategy that
should be formally explored in clinical practice.
Introduction
Nonalcoholic fatty liver disease (NALFD) is increasingly common, afflicting no less than 1 in 5
people living in Western nations. [1–3] In America, the respective prevalence of steatosis and
steatohepatitis is 46% and 12% and rising[4,5] and outpatient visits for the primary purpose of
NAFLD management have doubled of late.[3,6] The contemporary management of patients
with NAFLD is defined by two key features. First, there is a lack of a definite therapeutic
modality beyond lifestyle modification. Second, advanced fibrosis is the only significant predic-
tor of long-term complications and excess mortality. [7,8] Accordingly, a major focus of clini-
cal care for patients with NAFLD should be the determination of those at highest risk for the
complications of advanced liver disease.[1,4]
The optimal strategy for the management of NAFLD would benefit from a multidisciplinary
approach to prioritize patients for specialists referral. Patients with advanced fibrosis must be
discovered and managed appropriately by providing intensified therapy and screening proce-
dures for hepatocellular carcinoma and portal hypertension. Liver biopsy, while still considered
a gold-standard, is not preferred by patients and is too costly and risky to be applied to a highly
prevalent condition.[9] We recently showed that two strategies for non-invasive assessment for
advanced fibrosis were cost-effective compared to usual care (biopsy).[10] In this model, we
used the NAFLD Fibrosis Score (NFS)[11]–a risk prediction algorithm based on simple blood
tests and body mass index (BMI)–and the combination of the NFS with vibration-controlled
elastography (VCTE)[12]–a Food and Drug Administration approved ultrasound-based tech-
nique for fibrosis risk assessment. At the same time, universal referral to a gastroenterologist
for such a common disease is untenable. Ideally, primary care physicians would recognize and
manage early disease while gastroenterologists are referred patients with advanced liver
disease.
Increasingly, reports are identifying the feasibility of screening for advanced liver disease in
the primary care setting. [13,14] Doycheva and colleagues used magnetic resonance imaging
(MRI) techniques in a cohort of consecutive diabetic patients enrolled from primary care clin-
ics in San Diego.[14] They identified that 7.1% of patients were at risk for advanced fibrosis
based on liver stiffness measurements. Kwok et al screened 1918 patients from Hong Kong
with diabetes for the presence of NAFLD and advanced fibrosis with vibration-controlled elas-
tography (VCTE) based techniques, 17.1% of whom were identified as high risk for advanced
fibrosis.[13] While only 94 of these patients underwent biopsy, half of them had F3-F4 fibrosis.
[13,14] The cost-effectiveness of this strategy is unknown. Indeed, the cost of adopting a new
technology in the primary care setting is unclear. Furthermore, non-invasive tests can yield
both false-positive and false-negative results, the long-term implications of which are
unknown.
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quality adjusted life-years; HCC, Hepatocellular
carcinoma.
Herein, this study compares the cost-effectiveness of multiple strategies for the evaluation of
patients with NAFLD in the primary care clinic or the referral setting using the NFS, VCTE,
and their combination to the current standard of percutaneous liver biopsy.
Methods
We developed a probabilistic decision analytical microsimulation state-transition model[15]
using dedicated software (DATA 3.5, TreeAge, Williamstown, MA). The analysis was per-
formed according to published guidelines.[16,17] We simulated a cohort of 10,000 50-year old
patients evaluated in the primary care clinic for elevated liver enzymes (>40 IU/L) and liver
ultrasound consistent with steatosis due to NAFLD. This model recapitulated the natural his-
tory of NAFLD over 30 years All patients had a negative evaluation for excessive alcohol intake,
hepatitis C, hepatitis B, drug-induced liver injury or hemochromatosis. We assume that
patients with decompensated cirrhosis have been diagnosed clinically and managed accord-
ingly. We assume that prior to entry into the model each patient was observed during a trial of
lifestyle modification with persistent elevations in their liver enzyme elevation when reassessed
after a six-month period. All patients have NAFLD in this model with an unknown fibrosis
stage. The costs and benefits considered from the societal perspective.
We compared the following seven evaluation strategies: 6 noninvasive strategies (NFS
alone, VCTE alone, combined NFS and VCTE; each in the PCP and Liver clinic), and liver
biopsy in the liver clinic (Fig 1).[4,12] Each of the non-invasive strategies assigns patients into
one of three categories: low, indeterminate and high risk of advanced fibrosis. The clinical deci-
sions associated with each non-invasive strategy included referral to or retention in liver clinic
for advanced fibrosis and referral back to or retention in the PCP office for early stage fibrosis.
Consistent with expert recommendations, only the patients with indeterminate non-invasive
results are offered a liver biopsy.[12,18] Test characteristics and clinical decision criteria are
detailed in Table 1.
Each patient enters into the microsimulation state-transition model to simulate the clinical
and economic outcomes associated with each clinical decision (Fig 2). Patients stratified as
high risk for advanced liver disease (true and false positives) are followed closely by specialists
and incur increased costs and decreased utilities associated with care for advanced liver disease
(e.g. specialist visits, screening tests). Patients classified as low-risk are followed by their pri-
mary care physicians. Regardless of stratification, all patients follow the clinical trajectory of
their true disease-stage.
Ethics
This study does not include human subjects research.
Definition of Terms
The goal of this analysis is to model two outcomes simultaneously based on the generation of
discounted costs (2014 US dollars) and discounted quality adjusted life years (QALY) that
accrue to our cohort over time. Each model input which governs a patient's natural history is a
probability and beyond that there is a distribution of values (uncertainty) for most clinical vari-
ables—e.g. confidence intervals or ranges of values in the literature. For this reason, the model
is called a microsimulation—which follows the stochastic movements of individual subjects
through the chances of developing clinical outcomes—and a probabilistic analytic model
which analyzes 10,000 random samples within each parameter’s distribution. Accordingly, this
method repeats the analysis with 10,000 permutations of the variable inputs, thereby perform-
ing sensitivity analyses for each variable within its distribution. The end result is the probability
Cost-Effective Evaluation of NAFLD by PCP
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of cost-effectiveness for a given strategy in the overall set of simulations. The relative cost-effec-
tiveness of the strategies, in turn, are adjudicated with reference to a society’s willingness-to-
pay (WTP) threshold. The WTP threshold is the amount of money per person that society is
willing to pay to adopt a new clinical strategy for an additional QALY over the current accept-
able strategy. Finally, we calculated a metric called the population ‘expected value of perfect
information’ (EVPI). The population EVPI is a reflection of the benefit derived from further
research and is therefore a measure of the uncertainty in this analysis.
State-Transition probabilities
Details regarding the transition probabilities in the microsimulation model are described in
detail within the supplementary methods and supplementary table 1 (Table A in S1 Appendix).
In brief, the natural history of NAFLD was simulated utilizing published data. Patients with
NASH could regress to NAFLD. Similarly, patients with advanced fibrosis could regress to
NASH without advanced fibrosis. The rate of regression with lifestyle changes was derived
from longitudinal cohort studies utilizing sequential biopsies and subsequently converted to
probabilities. [19,20] In our model, patients with cirrhosis could not regress to an earlier stage
of disease. The annual rate of fibrosis progression was abstracted from a meta-analysis by
Fig 1. Flowchart of Patient Evaluation By Strategy.
doi:10.1371/journal.pone.0147237.g001
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Singh et al: 0.07 fibrosis stages (95% CI, 0.02–0.11) for simple steatosis and 0.14 fibrosis stages
(95% CI, 0.07–0.21) for those with NASH.[21]
Treatments and screening tests could modify the natural history. Both lifestyle interventions
and vitamin E are associated with improvement of histological inflammation,[19,22,23] the
magnitude of which was derived from a randomized control trial comparing both modalities.
[19] In accordance with published guidelines, we restricted vitamin E to patients with biopsy-
proven NASH.[4,19] As vitamin E does not lead to regression of advanced fibrosis,[19] these
patients with were not candidates for therapy. Patients who were falsely 'upstaged' by their risk
stratification test are therefore not offered vitamin E. Adherence to either lifestyle interventions
or vitamin E therapy is assumed to be 50% based on estimates from the World Health Organi-
zation.[24] Patients with advanced fibrosis are screened for hepatocellular carcinoma (HCC).
In accordance with a recent meta-analysis, patients who were correctly identified as having
advanced fibrosis and were followed by a gastroenterologists experienced increased likelihood
of early stage HCC detection (odds ratio (OR) 2.08 95% CI (1.80–2.37) and curative treatment
(OR 2.24 95% CI (1.99–2.52)).[25] The costs of care and utilities associated with each state and
strategy are detailed in the supplementary methods (Tables B-C in S1 Appendix).
Table 1. Estimates of Test Performance and Disease Prevalence for the Model.
Model Variable Estimate (%) Reference
Disease Stage Prevalence
Cirrhosis 0.06 [26], local data
Advanced (METAVIR 3) Fibrosis 0.11 [26], local data
NASH without Advanced Fibrosis 0.37 [26], local data
Simple Steatosis 0.47 [26], local data
Liver Biopsy Sensitivity and Speciﬁcity
Advanced Fibrosis 0.85 and 0.89 [27]
NASH 0.88 and 0.74 [27]
VCTE
Sensitivity and Speciﬁcity for Advanced Fibrosis 0.95 and 0.77 Local data
Indeterminate results—AdvancedFibrosis 1.0 Local data
Indeterminate results—NASH 0.21 Local data
Indeterminate results—Simple Steatosis 0.11 Local data
NFS
Sensitivity and Speciﬁcity for Advanced Fibrosis 0.21–0.43 and 0.96 [11], local data
Indeterminate results—Advanced Fibrosis 0.57–0.62 [11], local data
Indeterminate results—NASH 0.25–0.46 [11], local data
Indeterminate results—Simple Steatosis 0.06–0.25 [11], local data
VCTE and NFS
Sensitivity and Speciﬁcity for Advanced Fibrosis 0.19–0.83 and 0.99–1.0 [31], local data
Indeterminate results—AdvancedFibrosis 0.48–0.81 [31], local data
Indeterminate results—NASH 0.46–0.55 [11], local data
Indeterminate results—Simple Steatosis 0.06–0.37 [11], local data
The values presented are for the base-case estimate. In the microsimulation model, each value is given a
wide distribution that is sampled 10, 000 times.
NASH = Nonalcoholic Steatohepatitis, NFS = NAFLD Fibrosis Score, VCTE = Vibration Controlled
Transient Elastography
doi:10.1371/journal.pone.0147237.t001
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Disease-Stage prevalence
The population assessed in this model reflects patients who would otherwise be referred for
consultation after a preliminary evaluation for elevated liver function tests in the setting of
NAFLD. All patients have NAFLD. As previously published we derived the relative proportion
of patients with simple steatosis, NASH without advanced fibrosis (METAVIR stage 0–2 fibro-
sis), advanced fibrosis (METAVIR stage 3 fibrosis) and cirrhosis from a cohort of 431 patients
seen at our referral clinic from 1996–2013.[26] The combined proportion from these cohorts
with simple steatosis, NASH without advanced fibrosis, advanced fibrosis, and cirrhosis are,
respectively, 46.6% (201), 36.7% (158), 11.1% (48), and 5.6% (24).
Strategy Characteristics
Liver biopsy. Liver biopsy is also susceptible to false positives and false negatives in the
evaluation of NAFLD.[27] These values are described in Table 1. Further details are available
in the supplementary methods (S1 Appendix). As the test characteristics of biopsy following a
non-invasive risk-stratification are unknown, we assumed perfect biopsy performance in the
non-invasive strategies.
VCTE. VCTE generates a discrete liver stiffness measurement. Different studies utilize dif-
ferent cutoffs for advanced fibrosis and cirrhosis. [28–30], The test characteristics are those
from our center as published elsewhere.[10] We determined that a liver stiffness of 9.9 kPa was
an optimal cutoff for advanced fibrosis (F3-F4). The range of indeterminate values have been
suggested by expert opinion but have not been formally studied.[18] For our purposes, we used
an indeterminate range of 20%, meaning that all patients with liver stiffness measurements
between 7 and 9.8 kPa were considered indeterminate for advanced fibrosis. The technical
details pertaining to the performance of VCTE and the statistical interpretation of the optimal
cutoffs are presented in the supplementary methods (S1 Appendix).
NFS. The NAFLD Fibrosis Score is a readily available online calculator to risk-stratify
patients with NAFLD for the presence of advanced liver disease. The validated test characteris-
tics of the NFS strategy were derived from two sources: the landmark study by Angulo and
Fig 2. A Simplified Depiction of the Microsimulation State-Transition Model.HCC = Hepatocellular
carcinoma; NAFLD = Nonalcoholic Fatty Liver Disease; NASH = Nonalcoholic Steatohepatitis.
doi:10.1371/journal.pone.0147237.g002
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colleagues[11] and our cohort. Similar to VCTE, indeterminate results are those with high-neg-
ative values. These values are summarized in Table 1. Further information is available in the
supplementary methods (S1 Appendix).
NFS and VCTE. The combination of NFS and VCTE with liver biopsy for indeterminate
results has been evaluated in a prospective study of Italian patients.[31] We applied this strat-
egy to our cohort and the resultant test characteristics are described in Table 1. For the purpose
of the model we used a distribution based on values derived from the paper by Petta et al as
well as our cohort.[31] The presence or absence of advanced fibrosis is defined by concordance
between the tests; indeterminate results from the combination strategy can indicate either test
discordance (positive and negative) or indeterminate results from either test. If VCTE is unfea-
sible, then clinical decisions follow the strategy defined by NFS alone. See the supplementary
methods for the determination of the proportion of unfeasible VCTE exams (S1 Appendix).
Data Analysis. The model assumed an annual cycle length and terminated after 30 years.
All costs, life-years and utilities were discounted at a rate of 3%. Half-cycle correction was per-
formed. All costs were inflated to 2014 values and converted to American dollars. One-way
sensitivity analyses were performed for all variables and those which modified the outcome of
the model were presented in the results.
The primary outcome is derived from probabilistic sensitivity analyses which were per-
formed using Monte Carlo microsimulation of 10,000 patients with 10,000 samples taken from
the input parameter distributions. We chose a conventional WTP threshold of $100,000.[32]
We determined the expected value of perfect information (EVPI) as described in the supple-
mental methods (S1 Appendix).
The secondary outcome is correct classifications of advanced fibrosis per biopsy performed.
In this model, we re-ran our microsimulation as a simple decision tree to determine the num-
ber of biopsies needed (e.g. cost) and the proportion of patients with correct classification of
advanced fibrosis (i.e. effectiveness). This model does not assess differences between manage-
ment in the PCP or referral clinic and instead focuses strictly on the performance of NFS,
VCTE, NFS combined with VCTE and usual care (biopsy), penalizing poor sensitivity. It is
also a microsimulation of 10,000 patients with 10,000 samples taken from the input parameter
distributions pertinent to stratification test characteristics.
Results
Compared to the standard care of performing a liver biopsy, all noninvasive strategies are cost-
effective (Table 2). Strategies involving triage by the primary care physician (PCP) are less
Table 2. The Cost and Effect of Non-invasive Evaluations of Nonalcoholic Fatty Liver Disease (NAFLD) Compared to Usual Care (Liver Biopsy) in
the Primary Care and Referral Setting.
Strategy Cost ($) Effect (QALY) Incremental Cost ($) Incremental Effect (QALY)
Usual Care 98,815 13.67 +13,585 -0.57
VCTE(after referral) 97,881 13.74 +12,651 -0.50
VCTE(PCP ofﬁce) 96,478 13.74 +11,248 -0.50
NFS/VCTE (after referral) 96,334 13.97 +11,104 -0.27
NFS/VCTE(PCP ofﬁce) 94,942 13.97 +9,711 -0.27
NFS(after referral) 87,349 14.23 +2,118 -0.01
NFS(PCP ofﬁce) 85,231 14.24
Incremental costs and QALY reference a common baseline (usual care)
NFS = NAFLD Fibrosis Score, QALY = quality adjusted life-years, VCTE = Vibration Controlled Transient Elastography
doi:10.1371/journal.pone.0147237.t002
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costly than those requiring initial referral to a gastroenterologist. Whereas a strategy employing
the NFS alone by the PCP is cost-saving compared to usual care (referral for liver biopsy) by
$13,585 per person, it is also cost-saving compared to initial referral where the evaluation is
based on the NFS (by $2,118 per person). The NFS alone performed in the PCP’s office is a
‘dominant’ strategy with both cost-savings and increased effectiveness. The cost per QALY of
the NFS is $5,985 in the PCP office and $6,138 after referral while usual care with liver biopsy
costs $7,229. A cost-acceptability curve was generated to evaluate the cost-effectiveness of all
strategies in a probabilistic sensitivity analysis. At a willingness-to-pay (WTP) threshold of
$100,000 per QALY, the NFS alone strategy in the PCP office was dominant in 94.2% of sam-
ples, the NFS/VCTE strategy in the PCP office was dominant in 5.6% and usual care in 0.2%.
While the non-invasive strategies are expected to be cost-saving, there is uncertainty in
these results. The population-based EVPI is moderate, demonstrating that there is benefit to be
derived from further research. At WTP of $100,000 per QALY, the EVPI is $142 Million.
The performance of each strategy relative to the number of correct diagnoses provided is
detailed in Table 3. The NFS based strategies yield the best biopsy-to-correct classification
ratios (3.5). Both usual care and the NFS/VCTE strategy yield more correct classifications.
However, for each additional correct classification of advanced fibrosis related to NFS based
strategies, the NFS/VCTE costs 3 additional biopsies and usual care costs 37. One-way sensitiv-
ity analyses were performed to explore these tradeoffs. The rate of VCTE failure before which
it leads to fewer biopsies and higher correct classification rates than NFS based strategies is
17.5%. With current test characteristics, NFS leads to fewer biopsies than VCTE based strate-
gies up to a 59% prevalence of advanced fibrosis.
Discussion
The non-invasive evaluation of NAFLD using the NFS with or without VCTE is a cost-effective
strategy for the patient-centered risk stratification of an increasingly common disease.[10] In
this study of seven strategies comparing evaluation by primary care physicians (PCPs) and gas-
troenterologists, the use of NFS alone by the PCP was the most cost-effective strategy followed
by the combination of NFS with VCTE (also by the PCP). These data demonstrate that tremen-
dous costs are saved when a model of NAFLD care is applied where primary care physicians
would recognize and manage early disease, referring to gastroenterologists the patients with
advanced liver disease.
Our study adds to and extends the prior literature on the evaluation and management of
NAFLD/NASH in two principle ways. First, we previously showed that the use of non-invasive
indices was cost-effective in the referral setting.[10] This model extends that work by claiming
Table 3. Strategy Performance in a cohort of 10,000 patients.
Strategy Number of
biopsies
Correct Classiﬁcation of
Advanced Fibrosis
Incremental
Biopsies
Incremental Correct
Classiﬁcations
Incremental Biopsy to Correct
Classiﬁcation Ratio
Usual
Care
10,000 9,400 +7,357 +200 37
VCTE 3,485 8,400 +815 -800 *
NFS/
VCTE
3,507 9,500 +864 +300 3
NFS 2,643 9,200
NFS = Nonalcoholic Fatty Liver Disease Fibrosis Score, VCTE = Vibration Controlled Transient Elastography
*—negative incremental ratios are not calculated
doi:10.1371/journal.pone.0147237.t003
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additional cost-savings when PCPs participate in the risk-stratification of NAFLD. The benefits
of widespread risk-stratification in the primary care setting are substantial for two major rea-
sons. First, recent studies have demonstrated that when PCPs screen patients at risk for
NAFLD—including those with normal liver enzymes[14]–the prevalence of advanced liver dis-
ease is high. Second, late referrals, which make up 15–80% of referrals in prior studies, are asso-
ciated with suboptimal outcomes,[33] particularly as it relates to the lack of screening for HCC.
Furthermore, up to 20% of patients referred to a specialist will not attend their visit.[34] While
this model requires that PCPs accurately identify patients with NAFLD among those present-
ing with elevated liver enzymes, several studies have shown that PCPs are comfortable rou-
tinely excluding other causes of liver disease.[35–37]
Second, these data shed light on the reasons for the NFS’ robust performance. The NFS
was developed by Angulo as a means to avoid liver biopsy except for those patients with
indeterminate results.[11] VCTE can accomplish the same goals.[38] However, while VCTE
offers an excellent negative predictive value, it is susceptible to false-positives, particularly
owing to the contribution of inflammation and steatosis to liver stiffness.[39,40] These data
demonstrate that by avoiding over-staging, the NFS and NFS/VCTE strategies are the most
likely to identify high risk patients while minimizing false-positives and the need for biop-
sies. Unlike for patients with hepatitis C where over-staging may lead to unforeseen benefits
such as approval for antiviral therapy, there are limited benefits for a patient with uncompli-
cated NAFLD being misclassified as having advanced fibrosis. While evaluation by a special-
ist and screening for liver complications has measurable health benefits, it is also costly and
associated with the minor decrements in quality of life associated with frequent medical
appointments. As long as the available data supports a generally benign natural history for
patients with NAFLD, cost-effectiveness will be achieved by cost-containing strategies (i.e.
NFS).
This study must be evaluated within the context of the study design. First, this model did
not assess the benefits of controlled attenuation parameter (CAP) for VCTE which could iden-
tify patients with steatosis.[41] Nor did we evaluate MRI which can combine effective evalua-
tions for steatosis and fibrosis in the same examination.[14] Both techniques, not yet approved
for clinical use, are likely promising and should be explored with further clinical data before
cost-effectiveness analysis. Second, data regarding the natural history of NAFLD is limited,
particularly for patients with normal liver enzymes, and therefore multiple base-case estimates
of the disease-stage prevalence, response to therapy and the performance of non-invasive diag-
nostics in patients without elevated liver enzymes were not possible. Accordingly, it is unclear
whether these data are generalizable for the screened population. Third, this model should be
contrasted with our prior work in several ways. First, the rate of fibrosis stage progression has
received greater clarity owing to a recent meta-analysis by Singh and colleagues which now
includes the possibility of NAFLD without NASH progressing directly to advanced fibrosis.
[21] Second, in view of recent data on the benefit of hepatocellular cancer screening, we mod-
eled a survival benefit for correct classification of advanced fibrosis vis-à-vis earlier stage diag-
nosis.[25] Third, we used our own experience with VCTE in the US to determine the rate of
failed examinations which is 3 times the prior published estimate.[10] Fourth, we modelled the
performance of NFS and VCTE in the same cohort instead of the prior dependence on pub-
lished data. Taken together, these modifications result in incremental but significant improve-
ments in a model which strives to recapitulate the natural history of NAFLD after a one-time
risk stratification.
In conclusion, both the NFS and the combination of NFS with VCTE are biopsy-sparing,
cost-effective tools in the evaluation and management of NAFLD in the primary care setting.
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